PRANDIMET
LOE ApproachingNDAORALTABLET
Approved
Jun 2008
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed Yesterday · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PRANDIMET is an oral tablet combination product approved by Novo Nordisk in 2008 for type 2 diabetes management. The product represents a fixed-dose combination approach to glycemic control in diabetic patients. Specific mechanism of action and indication details are not available in current data.
LOE Approaching
Product is approaching loss of exclusivity with moderate competitive pressure (30%), suggesting defensive positioning and potential downsizing of brand team resources.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
PRANDIMET currently has zero linked job openings, reflecting its mature lifecycle and approaching LOE status. Career opportunities on this brand are limited and likely focused on defensive commercial strategies rather than growth initiatives.
Brand ManagerField Sales Representative
Worked on PRANDIMET at Novo Nordisk? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.